Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elatol
- Development stage
- Unknown
- Lead developer
- University of Miami Miller School of Medicine
01
Overview
elatol: sourced facts only. name: "In vitro studies showed that elatol inhibits eIF4A1 helicase activity, suppressing cytoplasmic cap-dependent translation initiation." [DOI:10.1158/1538-7445.am2022-3775]; target: "In vitro studies showed that elatol inhibits eIF4A1 helicase activity, suppressing cytoplasmic cap-dependent translation initiation." [DOI:10.1158/1538-7445.am2022-3775]; developer: "1University of Miami Miller School of Medicine, Miami, FL." [DOI:10.1158/1538-7445.am2022-3775]; stage: "This was confirmed in CML and acute lymphoblastic leukemia (ALL) cell lines whose 24-hour elatol LD50 ranged from high nanomolar to low micromolar concentrations." [DOI:10.1158/1538-7445.am2022-3775]
02
Targets
EIF4A1 (Eukaryotic translation initiation factor 4A1)
Beyond the preview
Go deeper on elatol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elatol.